Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

  • Showing results for and ii pylypenko. Your search for Andrii Pylypenko retrieved no results.
1.

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.

Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G, Okamoto R, Nakahara S, Hu P, Appiani C, Nemat S, Cavalli F; LYM-3002 investigators.

Lancet Oncol. 2018 Nov;19(11):1449-1458. doi: 10.1016/S1470-2045(18)30685-5. Epub 2018 Oct 19.

PMID:
30348538
2.

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study.

Mohty M, Terpos E, Mateos MV, Cavo M, Lejniece S, Beksac M, Bekadja MA, Legiec W, Dimopoulos M, Stankovic S, Durán MS, De Stefano V, Corso A, Kochkareva Y, Laane E, Berthou C, Salwender H, Masliak Z, Pečeliūnas V, Willenbacher W, Silva J, Louw V, Nemet D, Borbényi Z, Abadi U, Pedersen RS, Černelč P, Potamianou A, Couturier C, Feys C, Thoret-Bauchet F, Boccadoro M; EMMOS Investigators.

Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):e401-e419. doi: 10.1016/j.clml.2018.06.018. Epub 2018 Jun 25.

3.

Coupling fission and exit of RAB6 vesicles at Golgi hotspots through kinesin-myosin interactions.

Miserey-Lenkei S, Bousquet H, Pylypenko O, Bardin S, Dimitrov A, Bressanelli G, Bonifay R, Fraisier V, Guillou C, Bougeret C, Houdusse A, Echard A, Goud B.

Nat Commun. 2017 Nov 1;8(1):1254. doi: 10.1038/s41467-017-01266-0.

4.

Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study.

Verhoef G, Robak T, Huang H, Pylypenko H, Siritanaratkul N, Pereira J, Drach J, Mayer J, Okamoto R, Pei L, Rooney B, Cakana A, van de Velde H, Cavalli F.

Haematologica. 2017 May;102(5):895-902. doi: 10.3324/haematol.2016.152496. Epub 2017 Feb 9.

5.

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators.

N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038.

6.

Synthesis of a mixed-valent tin nitride and considerations of its possible crystal structures.

Caskey CM, Holder A, Shulda S, Christensen ST, Diercks D, Schwartz CP, Biagioni D, Nordlund D, Kukliansky A, Natan A, Prendergast D, Orvananos B, Sun W, Zhang X, Ceder G, Ginley DS, Tumas W, Perkins JD, Stevanovic V, Pylypenko S, Lany S, Richards RM, Zakutayev A.

J Chem Phys. 2016 Apr 14;144(14):144201. doi: 10.1063/1.4945561.

7.

Bandgap Tuning of Silicon Quantum Dots by Surface Functionalization with Conjugated Organic Groups.

Zhou T, Anderson RT, Li H, Bell J, Yang Y, Gorman BP, Pylypenko S, Lusk MT, Sellinger A.

Nano Lett. 2015 Jun 10;15(6):3657-63. doi: 10.1021/nl504051x. Epub 2015 May 18.

PMID:
25971956
8.

A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia.

Kipps TJ, Eradat H, Grosicki S, Catalano J, Cosolo W, Dyagil IS, Yalamanchili S, Chai A, Sahasranaman S, Punnoose E, Hurst D, Pylypenko H.

Leuk Lymphoma. 2015;56(10):2826-33. doi: 10.3109/10428194.2015.1030638. Epub 2015 May 12.

9.

Essential "ankle" in the myosin lever arm.

Pylypenko O, Houdusse AM.

Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):5-6. doi: 10.1073/pnas.1017676108. Epub 2010 Dec 21. No abstract available.

10.

Structure of doubly prenylated Ypt1:GDI complex and the mechanism of GDI-mediated Rab recycling.

Pylypenko O, Rak A, Durek T, Kushnir S, Dursina BE, Thomae NH, Constantinescu AT, Brunsveld L, Watzke A, Waldmann H, Goody RS, Alexandrov K.

EMBO J. 2006 Jan 11;25(1):13-23. Epub 2006 Jan 5.

11.

Structure of the extremely slow GTPase Rab6A in the GTP bound form at 1.8A resolution.

Bergbrede T, Pylypenko O, Rak A, Alexandrov K.

J Struct Biol. 2005 Dec;152(3):235-8. Epub 2005 Nov 18.

PMID:
16332443
12.

Structure of Rab GDP-dissociation inhibitor in complex with prenylated YPT1 GTPase.

Rak A, Pylypenko O, Durek T, Watzke A, Kushnir S, Brunsveld L, Waldmann H, Goody RS, Alexandrov K.

Science. 2003 Oct 24;302(5645):646-50.

Supplemental Content

Loading ...
Support Center